Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01920191

Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma

Phase I/II Study of Intradermal IMA950 Peptide-based Vaccine Adjuvanted With Intra Muscular Poly-ICLC in Combination With Temozolomide in Newly Diagnosed HLA-A2 Glioblastoma Patients

Sponsor: Immatics Biotechnologies GmbH

Conditions CNS Tumor, Adult

Interventions IMA 950 Immunomonitoring Poly ICLC

Updated 6 times since 2017 Last updated: Apr 19, 2016 Started: Aug 31, 2013 Primary completion: Mar 31, 2016 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01920191, this PHASE1/PHASE2 trial focuses on CNS Tumor, Adult and remains completed. Sponsored by Immatics Biotechnologies GmbH, it has been updated 6 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Mar 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Mar 2022 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immatics Biotechnologies GmbH
Oncovir, Inc.
University Hospital, Geneva

Data source: University Hospital, Geneva

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Geneva, Switzerland